By Prof. Francesco Sanguedolce (IT), Chair of the EAU Section in Urological Imaging
After the unprecedented success of the last two annual meetings of the EAU Imaging Section within the EMUC scientific programme, expectations for this year’s meeting are very high. Efforts from the scientific committee have been made to build a comprehensive 2025 scientific programme, with artificial intelligence (AI) in onco-urology clinical practice as a key topic.
Artificial intelligence
Imaging is, in fact, the field where AI is most actively explored, and we will demonstrate how this technology can fundamentally support clinicians and surgeons in optimising the patient journey through cancer care. The meeting will open with a dedicated session on this topic, and delegates will also have the chance to learn more about useful AI applications throughout the rest of the scientific programme.
Screening and tissue sampling
Plenary 2 will feature a progress update of screening programmes across the main urological cancers, such as the Yorkshire screening trial for renal cancer using non-contrasted CT scan. A special “out-of-the box” lecture will share early experiences with whole-body MRI for general screening.
Imaging is advancing in such a way that tissue sampling is becoming less necessary for decision-making. A dynamic Plenary Session 3 will feature rapid fire debates based on clinical cases, questioning whether we can skip TURBT or biopsy before major interventions.
New recommendations on prostate biopsy have been released by the EAU Guidelines. However, clear standardisation of the procedural steps of a perilesional biopsy – and clarity on how prostate biopsy findings should guide localised treatment are still lacking. A consensus process has been initiated, and its main results will be shown during an exclusive review at the EMUC meeting.
Imaging abstract submissions
The 6 best abstracts on imaging in urological cancers will be awarded in the special session, so be sure to submit your imaging abstract before 1 August 2025 (23:59 CEST). The top 3 abstracts will win a prize.
Nuclear medicine and precision therapy
Nuclear medicine continues to evolve quickly in the field of imaging of urological cancers. A special joint session has been organised with the European Association of nuclear medicine and will highlight a summary from the recent APCCC diagnostic meeting, showcasing the most innovative tracers for the management of renal cancer.
Precision therapy in bladder cancer will be another hot topic, with exploration of how urologists can optimise their surgeries by selecting the right patients for an imaging-guided surgery or choosing the right targeted systemic treatment to the most suitable patient.
Game-changers
2025 to date has also seen a significant number of game-changing publications on imaging in urological cancers. In the final session of the meeting, delegates will have the unique opportunity to engage directly with the lead authors and ask questions about their findings and how to integrate these findings into everyday practice.
All of this is only possible thankfully to the world-class experts coming from all over the world and from different disciplines, who will fascinate the audience with their work and the dynamic interaction.
—-
See the imaging sessions, and the full EMUC25 scientific programme.
